Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

318.85DKK
21 May 2019
Change (% chg)

kr.1.95 (+0.62%)
Prev Close
kr.316.90
Open
kr.317.00
Day's High
kr.319.05
Day's Low
kr.316.05
Volume
1,676,028
Avg. Vol
2,367,751
52-wk High
kr.349.70
52-wk Low
kr.265.15

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.51
Market Cap(Mil.): kr.610,749.88
Shares Outstanding(Mil.): 1,962.56
Dividend: 3.00
Yield (%): 2.44

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 20.21 29.30 32.55
EPS (TTM): 15.40 -- --
ROI: 76.65 14.23 13.82
ROE: 84.84 15.46 15.24

Novo Nordisk profit tops forecast as new diabetes drug shines

COPENHAGEN Danish drugmaker Novo Nordisk beat first-quarter operating profit forecasts on Friday, helped by higher sales of its biggest new drug hope, a treatment for type 2 diabetes.

May 03 2019

UPDATE 2-Novo Nordisk profit tops forecast as new diabetes drug shines

COPENHAGEN, May 3 Danish drugmaker Novo Nordisk beat first-quarter operating profit forecasts on Friday, helped by higher sales of its biggest new drug hope, a treatment for type 2 diabetes.

May 03 2019

Drugmaker Novo Nordisk first-quarter profit beats expectations

COPENHAGEN, May 3 Danish drugmaker Novo Nordisk posted first-quarter operating profit above forecasts on Friday as it sold more of its newest innovative drug to combat diabetes and nudged up its 2019 outlook reported in Danish crowns.

May 03 2019

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Apr 12 2019

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN, April 12 Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Apr 12 2019

Only first whistleblower entitled to collect in Novo Nordisk settlement – judge

A former Novo Nordisk employee deserves 15 percent of a $46.5 million settlement between the drugmaker and the U.S. Justice Department resolving claims its marketing downplayed its diabetes medication Victoza's cancer risks, a federal judge has ruled.

Apr 09 2019

Novo Nordisk submits diabetes pill for U.S. approval

COPENHAGEN Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for approval in the United States.

Mar 20 2019

UPDATE 1-Novo Nordisk submits diabetes pill for U.S. approval

COPENHAGEN, March 20 Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for approval in the United States.

Mar 20 2019

Novo Nordisk submits diabetes pill for U.S. approval

COPENHAGEN, March 20 Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for U.S. approval.

Mar 20 2019

Novo Nordisk, Sanofi must face lawsuit over insulin pricing: judge

A federal judge on Friday cleared the way for consumers to proceed with a proposed class action accusing drug manufacturers Sanofi SA and Novo Nordisk of fraudulently inflating prices for insulin.

Feb 15 2019

Earnings vs. Estimates